Evidence map›Paper›PMID 32258088›Full record

ArticleWorld journal of clinical cases2020

Hepatoid adenocarcinoma of the stomach: Thirteen case reports and review of literature.

Zheng-Rong Zhang, Jian Wu, Han-Wen Li, Tao Wang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Hepatoid adenocarcinoma: A wolf in hepatocellular carcinoma's clothing.JGH open : an open access journal of gastroenterology and hepatology · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Gastric hepatoid adenocarcinoma with multiple liver metastasis: a case report.Gastroenterology and hepatology from bed to bench · 2021
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zheng-Rong ZhangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
Jian WuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China. wj4966@126.com.
Han-Wen LiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
Tao WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China.
Wannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the present study was to examine the clinical characteristics of hepatoid adenocarcinoma of the stomach (HAS) and its diagnosis, treatment, and prognosis. CASE SUMMARY: A retrospective analysis of 13 HAS cases was performed. The mean age of the 13 patients was 66.08 years, and 10 of the 13 patients were male. Prior to treatment, the alpha-fetoprotein levels in the serum were elevated in 7 patients, the tumour was located in the distal or gastric body in 11 patients, and the gastroscopy pathological results showed that 3 patients had poorly differentiated tumours and that 8 patients had moderately/poorly differentiated tumours. Abdominal CT scans showed local stomach wall thickening, and enlarged lymph nodes were visible around the stomach in 8 patients. Of the 13 patients, 11 underwent radical surgery. The clinical pathological staging was as follows: Stage II in 2 cases; stage III in 8 cases; and stage IV in 1 case. A total of 3 patients were lost to follow-up. Otherwise, as of the last follow-up, 3 patients had survived for 56 mo, and the other 7 patients failed to achieve long-term survival (survival period of 1-56 mo).

conclusionHAS is a special type of gastric cancer, and the prognosis of HAS has improved compared with past prognoses. Measurement of alpha-fetoprotein, early diagnosis, active surgical treatment, and application of new diagnostic and treatment techniques are conducive to improving the prognosis of HAS.

Indexed as

Alpha-fetoproteinCase reportHepatoid adenocarcinoma of the stomachStomach cancer

Identifiers

PMID32258088
PMCPMC7103972
OpenAlexW3013716356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.